Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir 1% Gel in Adolescent Females
NCT02245945Phase 1Withdrawn
- Sponsor
- CONRAD
- Primary completion
- Apr 2015
- Modality
- Implantable Devices, Transdermal Patches, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing TFV 1% gel with Placebo gel (2 arms). Primary endpoints: Changes in genitourinary adverse events at 12 weeks, Changes in soluble markers of inflammation in cervicovaginal fluid at 12 weeks and 1 more. Status: withdrawn.
02
Drugs
tenofovir gel
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02245945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245945.